18F-fluorodeoxyglucose positron emission tomography-computed tomography as a diagnostic tool in patients with cervical nodal metastases of unknown primary site: a meta-analysis

Surg Oncol. 2013 Sep;22(3):190-4. doi: 10.1016/j.suronc.2013.06.002. Epub 2013 Jul 11.

Abstract

Background: We performed a meta-analysis to evaluate the value of (18)F-fluorodeoxyglucose positron emission tomography-computed tomography ((18)FDG PET-CT) for the detection of primary sites in patients with cervical nodal metastases of unknown origin.

Methods: Studies were systematically searched for relevant PET-CT original articles in the MEDLINE and EMBASE databases. We calculated the primary tumor detection rate, sensitivity, specificity, and likelihood ratios for (18)FDG PET-CT. We also constructed the hierarchic summary receiver operating characteristic curve for (18)FDG PET-CT.

Results: This present study analyzed a total of 7 selected studies (246 patients). The primary tumor detection rate, sensitivity and specificity of PET-CT were 0.44 (95% confidence interval [CI] = 0.31-0.58), 0.97 (95% CI = 0.63-0.99), and 0.68 (95% CI = 0.49-0.83). Area under the curve was 0.83 (95% CI = 0.80-0.86).

Conclusions: (18)FDG PET-CT has high sensitivity and low specificity for the detection of primary sites in patients with cervical nodal metastases of unknown origin.

Keywords: Cervical carcinoma of unknown origin; Meta-analysis; PET-CT; Primary site.

Publication types

  • Review

MeSH terms

  • Fluorodeoxyglucose F18*
  • Humans
  • Lymph Nodes / pathology*
  • Lymphatic Metastasis
  • Meta-Analysis as Topic
  • Neoplasm Recurrence, Local / diagnosis*
  • Neoplasms, Unknown Primary / diagnosis*
  • Positron-Emission Tomography*
  • Prognosis
  • Radiopharmaceuticals*
  • Tomography, X-Ray Computed*

Substances

  • Radiopharmaceuticals
  • Fluorodeoxyglucose F18